PhRMA's new report counts each cancer drug in the US pipeline, which has now swelled to over 1,000 in the clinic
Cancer drugs are crowding in to an already cramped pipeline this year, with hundreds of immuno-oncology hopefuls now taking a shot at clinical testing. That’s according to a new cancer report from PhRMA, which counted 1,120 oncology drugs in the clinic so far this year — a massive increase from previous years — and that’s just in the US.
For perspective, there were only 836 cancer therapies counted by PhRMA in 2015, which means the pipeline has swelled 34% in less than three years. The organization only counted drugs already in the clinic or awaiting review from the FDA. That means there’s a significant backlog of therapies in preclinical development, waiting to elbow their way into the fray.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.